Dec. 19 at 11:43 AM
$MIRA Ketamir‑2 Steps Forward The first key piece of the MIRA story is Ketamir‑2, an oral, patent‑pending ketamine analog designed to deliver ultra‑rapid antidepressant effects for some of the most difficult‑to‑treat patients: treatment‑resistant depression, major depression with suicidal ideation, & PTSD. MIRA has already reported positive topline results from the single‑ascending‑dose portion of its Phase 1 trial in healthy volunteers, showing Ketamir‑2 was safe & well‑tolerated across all tested dose levels. On the back of that success, the company has initiated the multiple‑ascending‑dose (MAD) Phase 1 study, a critical step toward moving Ketamir‑2 into a Phase 2a trial in a lead indication. For traders, this matters because it de‑risks the program’s basic safety profile in humans & sets up a chain of near‑term catalysts: MAD data, final Phase 1 readouts, & first‑in‑patient Phase 2a results. Each of those steps can be a sentiment valuation inflection point in small‑cap biotech.
